Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies


At Shield we truly understand the value of global partnerships

About Us

Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia through our approved product
Feraccru®/Accrufer® Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.

Approved Products

Our approved product is a novel, stable, non-salt based oral therapy for the treatment of iron deficiency and is approved in the European Union, the United States and Switzerland.  In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. We are currently selecting a commercial partner for the US where the product will be marketed as Accrufer™.

Our product pipeline


PT20 is a novel iron-based phosphate binder, that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease. PT20 has successfully completed one pivotal study and now requires one further pivotal study after which regulatory filings for marketed approval would be expected to follow.

PT30 and PT40

PT30 is a concept that is aimed at developing a hypo-allergenic IV Iron Therapy, whilst PT40 is being developed to be the first generic version of iron sucrose. Both assets are in preclinical development.

Partnering Opportunities

If you are interested in working with us to make Feraccru®/Accrufer® and our other pipeline candidates available to as many patients as possible please contact us.